KOLINPHARMA® expands product portfolio with DOLATROX® hcc, DOLTENDIX® and XINPROX®

New product launches in 2021

KOLINPHARMA® expands its orthopedic line with the launch of its first medical device DOLATROX® hcc based on hyaluronic acid, chondroitin sulfate and cyclodextrine and new nutraceutical product DOLTENDIX® sachets, based on bioactive peptides from collagen, astaxanthin, trans-resveratrol and vitamin C, formulated for the well-being od the tendons. Also KOLINPHARMA® expands its uro-gynaecological line with launch of XINPROX®  based on Graminex® G63®, quercetin, alpha-lipoic acid, L-tryptophan, formulated for the well-being of the prostate.